Vergoeding 2018-2022 voor ATC-subgroep A10AE : Langwerkende insulines voor injectie
- Raming voor de totale Zvw-populatie
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| A10AE04 Insuline glargine (Abasaglar ®) | 43.865.900 | 41.164.100 | 39.586.600 | 34.040.400 | 34.709.400 |
| A10AE05 Insuline detemir (Levemir ®) | 12.206.700 | 10.395.100 | 8.986.600 | 7.405.700 | 7.065.500 |
| A10AE06 Insuline degludec (Tresiba ®) | 18.504.900 | 19.282.400 | 19.547.700 | 19.769.600 | 21.655.600 |
| A10AE54 Insuline glargine met lixisenatide (Suliqua ®) | 428.860 | 657.230 | 451.990 | 346.850 | 261.620 |
| A10AE56 Insuline degludec met liraglutide (Xultophy ®) | 3.567.700 | 3.521.700 | 2.860.600 | 2.210.500 | 1.908.400 |
| Totaal | 78.574.060 | 75.020.530 | 71.433.490 | 63.773.050 | 65.600.520 |